Latest News and Press Releases

EU approves Novo Nordisk's Wegovy® pill as first oral GLP-1 for weight management; as well as ready-to-use pen for Wegovy 7.2 mg injection

Dublin, July 15, 2026 (GLOBE NEWSWIRE) -- The "Oral Obesity Therapies Market Report 2026" has been added to ResearchAndMarkets.com's offering. The Oral Obesity Therapies Market Global Report...

Funding to advance AI-native drug R&D engine and pipelines, including MDR-001, an oral GLP-1 small-molecule in Phase III clinical trials in China.

Vivani Medical entered into agreement with Novo Nordisk to evaluate its miniature subdermal semaglutide (GLP-1) implant for weight management

Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535

Austin, TX, USA, July 03, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Antidiabetic Drugs Market Size, Trends, and Insights By Drug Class (Insulin,...

NorthStrive Biosciences Announces Positive Results from Phase III of AI-Driven Drug Discovery Program with Yuva Biosciences

Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach When combined with semaglutide, IBIO-610 drove...

Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Ka

Torino, Italy, June 29, 2026 – Resalis Therapeutics today announced the dosing of the first participant in a Phase 1b clinical study of its lead candidate, RES-010, a novel antisense oligonucleotide...